Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nayla Chaijale"'
Autor:
Samuel Frank, Karen E. Anderson, Hubert H. Fernandez, Robert A. Hauser, Daniel O. Claassen, David Stamler, Stewart A. Factor, Joohi Jimenez-Shahed, Hadas Barkay, Amanda Wilhelm, Jessica K. Alexander, Nayla Chaijale, Steve Barash, Juha-Matti Savola, Mark Forrest Gordon, Maria Chen
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 655-675 (2024)
Abstract Introduction Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington disease (HD). To enhance detection of safety signals across individual trials, integra
Externí odkaz:
https://doaj.org/article/86f74f75204d4fddb3bf5d6367615519
Autor:
Delbert G. Robinson, Mark Suett, Amanda Wilhelm, Nayla Chaijale, Kelli R. Franzenburg, Sanjay Gandhi, Blaine Cloud, Marko Mychaskiw
Publikováno v:
Advances in Therapy. 40:2249-2264
Autor:
Daniel Claassen, Hela Romdhani, Rajeev Ayyagari, Debbie Goldschmidt, Sarah Moroz, Adreanna Hernandez, Nayla Chaijale, Sam Leo
Publikováno v:
Sunday, April 23.
Autor:
Stacy Finkbeiner, Amanda Wilhelm, Mark Forrest Gordon, Hadas Barkay, Martha Sajatovic, Nayla Chaijale, Nicholas Gross
Publikováno v:
The American Journal of Geriatric Psychiatry. 30:360-371
BackgroundTardive dyskinesia (TD) is an involuntary movement disorder that is more prevalent in older patients. However, there is limited information on TD treatment for this population. In two 12-week pivotal trials (ARM-TD and AIM-TD), TD patients
Autor:
Hadas Barkay, Stacy Finkbeiner, Amanda Wilhelm, Jessica Alexander, Nayla Chaijale, Mark Forrest Gordon
Publikováno v:
CNS Spectrums. 27:239-240
IntroductionThe mechanism of tardive dyskinesia (TD) is complex and not well understood. Dopamine-receptor blockade in the nigrostriatal pathway may lead to a hyperdopaminergic state that can interfere with mechanisms of movement control, leading to
Publikováno v:
CNS Spectrums. 26:156-156
BackgroundThere are no established treatment guidelines for tardive dyskinesia (TD) based on movement severity. The 12-week ARM-TD and AIM-TD studies in TD patients with baseline Abnormal Involuntary Movement Scale (AIMS) total score (items 1–7)
Autor:
Hadas Barkay, Karen E. Anderson, Nayla Chaijale, Amanda Wilhelm, Juha-Matti Savola, Mark Forrest Gordon, Hubert H. Fernandez, Alexander F. Send
Publikováno v:
CNS Spectrums. 26:164-164
BackgroundDeutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly by 6 mg/day, from 12 to 48 mg/day, based on dyskinesia control and tolerability. This analysis compared the safety of deutetrabenazine during tit
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 313:389-394
The mechanisms and sites of action of epibatidine-induced antinociception and side effects are poorly understood. The present study tested the hypothesis that the serotonergic dorsal raphe nucleus is a site of action of epibatidine. Behavioral respon
Publikováno v:
The FASEB Journal. 25